Please try another search
For the nine months ended 30 September 2020, EidosTherapeutics Inc revenues decreased 100% to $127K. Net lossincreased from $18.9M to $81.8M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Research and development - Balan increase of 72%to $54.1M (expense), General and administrative increase of82% to $18.5M (expense).
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 0.13 | 0 | 0 | 0 |
Gross Profit | 0.13 | 0 | ||
Operating Income | -29.4 | -28.24 | -22.89 | -19.32 |
Net Income | -30.18 | -28.85 | -22.82 | -18.98 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 161.35 | 186.67 | 208.6 | 203.82 |
Total Liabilities | 38.49 | 37.36 | 33.74 | 32.39 |
Total Equity | 122.86 | 149.31 | 174.85 | 171.43 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -68.57 | -40.93 | -18.88 | -31.65 |
Cash From Investing Activities | -0.35 | -0.24 | -0.05 | -0.23 |
Cash From Financing Activities | 25.09 | 24.84 | 24.29 | 65.89 |
Net Change in Cash | -43.83 | -16.34 | 5.36 | 34.01 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review